# US 2023/0416725 A1 · Systems for gene editing and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0416725 A1
- Document ID: US20230416725A1
- Status: Published application
- Kind: A1
- Application number: 18/245,256
- Filed: 2021-09-14
- Published: 2023-12-28
- Earliest claimed: 2020-09-15
- Assignees: Rutgers, The State University of New Jersey
- Applicants: Rutgers, The State University of New Jersey
- Inventors: Peter J. Romanienko; Ghassan Yehia
- Web page: https://patentgrep.com/patent/US20230416725A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 5/0662: {Stem cells}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12Y 207/1103: Receptor protein serine/threonine kinase (2.7.11.30)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

This disclosure provides a novel gene editing method and system, termed dasCRISPR. dasCRISPR refines current approaches in gene editing by allowing an intended modification to be made in one genomic target while preventing modification to a second genomic target through protective sequestration. This balancing of repair and protection contributes to cellular survival by retention of one functional copy of a gene. Thus, dasCRISPR method as disclosed allows successful CRISPR gene editing of an intended modification at a target sequence by an active Cas polypeptide, while preserving specific genomic regions, protected by dCas polypeptide, from unintended modification

## Claims

### Claim 1

A system for gene editing, comprising:
a CRISPR-associated protein (Cas) polypeptide or a first Cas nucleotide sequence encoding a Cas polypeptide;
a nuclease-deficient Cas (dCas) polypeptide or a second Cas nucleotide sequence encoding a dCas polypeptide; and
a guide nucleotide sequence encoding or comprising a crRNA sequence capable of hybridizing with a first target sequence on a first allele and a second target sequence on a second allele and forming a complex with the Cas polypeptide and the dCas polypeptide,
wherein the Cas polypeptide binds to the first target sequence on the first allele and induces genetic modification in the first target sequence, and
wherein the dCas polypeptide binds to the second target sequence on the second allele and protects the second target sequence from modification and from the activity of the Cas polypeptide

### Claim 2 (depends on 1)

The system of claim 1, wherein the first target sequence comprises one or more mutations.

### Claim 3 (depends on 1)

The system of claim 1, wherein the first target sequence and the second target sequence are identical or the first target sequence comprises one or more mutations with respect to the second target sequence.

### Claim 4 (depends on 1)

The system of claim 1, wherein the genetic modification comprises an insertion of a stop codon, a point mutation, a deletion or an insertion.

### Claim 5 (depends on 1)

The system of claim 1, wherein the guide nucleotide sequence together with the Cas polypeptide or the dCas polypeptide are delivered to a cell or an embryo as a ribonucleoprotein complex.

### Claim 6 (depends on 1)

The system of claim 1, wherein the Cas polypeptide and the dCas polypeptide have a ratio of between about 1:100 and about 100:1.

### Claim 7 (depends on 6)

The system of claim 6, wherein the Cas polypeptide and the dCas polypeptide have a ratio of between about 1:10 and about 10:1, and optionally wherein the Cas polypeptide and the dCas polypeptide have a ratio of about 2:1, about 1:2, about 1:4, about 1:6, or about 1:8.

### Claim 8 (depends on 1)

The system of claim 1, wherein the first Cas nucleotide sequence and the second Cas nucleotide sequence are located on the same vector.

### Claim 9 (depends on 1)

The system of claim 1, wherein the guide nucleotide sequence is located on the same vector with the first Cas nucleotide sequence or with the second Cas nucleotide.

### Claim 10 (depends on 9)

The system of claim 9, further comprising a second guide nucleotide sequence, wherein the second guide nucleotide sequence and the second Cas nucleotide sequence are located on the same vector, and wherein the guide nucleotide sequence and the first Cas nucleotide sequence are located on the same vector.

### Claim 11 (depends on 1)

The system of claim 1, wherein the guide nucleotide sequence is a synthetic RNA molecule.

### Claim 12 (depends on 1)

The system of claim 1, wherein the first Cas nucleotide or the Cas polypeptide sequence and the second Cas nucleotide or the dCas polypeptide sequence are otherwise identical, except that the second Cas nucleotide or the dCas polypeptide comprises one or more mutations causing a deficiency in nuclease activity of the dCas polypeptide.

### Claim 13 (depends on 1)

The system of claim 1, wherein the Cas polypeptide and the dCas polypeptide belong to different CRISPR CAS families.

### Claim 14 (depends on 1)

The system of claim 1, wherein the Cas polypeptide is selected from the group consisting of a Cas9 nuclease, a Cpf1 nuclease, a Cas12a nuclease, a Cas12e nuclease, a CasX nuclease, a Cas12d nuclease, a CasY nuclease, a Cas12b nuclease, a C2C1 nuclease, a Cas12c nuclease, a C2C3 nuclease, a C2C4 nuclease, a C2C5 nuclease, a C2C6 nuclease, a C2C7 nuclease, a C2C8 nuclease, a C2C9 nuclease, a C2C10 nuclease, a Cas13a nuclease, a Cas13b nuclease, and a Cas13c nuclease.

### Claim 15 (depends on 1)

The system of claim 1, wherein the Cas polypeptide is a Cas9 nuclease.

### Claim 16 (depends on 14)

The system of claim 14, wherein the Cas9 nuclease is selected from the group consisting of Streptococcus pyogenes Cas9 (SpCas9), Staphylococcus aureus Cas9 (SaCas9), Neisseria meningitidis Cas9 (NmCas9), Actinomyces naeslundii Cas9 (AnCas9), and Streptococcus thermophilus Cas9 (StCas9).

### Claim 17 (depends on 1)

A host cell or cell line or progeny thereof comprising the system of claim 1.

### Claim 18 (depends on 17)

The host cell or cell line or progeny thereof of claim 17, comprising a stem cell or stem cell line.

### Claim 19 (depends on 1)

A composition comprising the system of claim 1.

### Claim 20 (depends on 1)

A method of modifying a target sequence of interest comprising delivering the system of claim 1 to the target sequence or a cell containing the target sequence and thereby inducing a modification in the target sequence.

### Claim 21 (depends on 20)

The method of claim 20, wherein the target sequence is located at genomic loci of interest.

### Claim 22 (depends on 20)

The method of claim 20, wherein the target sequence is part of a gene and the modification in the target sequence modulates the expression level or the function of the gene.

### Claim 23 (depends on 22)

The method of claim 22, wherein the modification in the target sequence increases or reduces the expression level or the function of the gene.

### Claim 24 (depends on 23)

The method of claim 23, wherein the gene is selected from the group consisting of p53, LOXL1, NOX4, SNX27, and Cathepsin B.

### Claim 25 (depends on 24)

The method of claim 24, wherein the modification on only one allele, while protecting the second allele, causes reduced DNA damage response (DDR) in hematopoietic stem cells and other cells, reduced cytokine expression, or reduced inflammation.

### Claim 26 (depends on 20)

The method of claim 20, the cell is a eukaryotic cell.

### Claim 27 (depends on 26)

The method of claim 26, wherein the cell is a plant, animal, or human cell.

### Claim 28 (depends on 20)

The method of claim 20, comprising delivering the system via particles, vesicles, or one or more viral vectors.

### Claim 29 (depends on 28)

The method of claim 28, wherein the one or more viral vectors comprise an adenovirus-based vector, a lentivirus-based vector, or an adeno-associated virus-based vector.

### Claim 30 (depends on 20)

The method of claim 20, wherein the target sequence comprises a genetic defect that is associated with a disease or a naturally occurring variant not associated with a disease.

### Claim 31 (depends on 30)

The method of claim 30, wherein the disease is cancer, a genetic disease or a neurodegenarative disease.

### Claim 32 (depends on 1)

A method of treating a disease of a subject caused by a genetic defect in a target sequence, comprising: administering the system of claim 1 containing the target sequence in a subject in need thereof and thereby inducing a modification in the target sequence.

### Claim 33 (depends on 32)

The method of claim 32, wherein the target sequence is located at genomic loci of interest.

### Claim 34 (depends on 32)

The method of claim 32, wherein the target sequence is part of a gene and the modification in the target sequence modulates the expression level and the function of the gene.

### Claim 35 (depends on 34)

The method of claim 34, wherein the gene is selected from the group consisting of p53, LOXL1, NOX4, SNX27, and Cathepsin B.

### Claim 36 (depends on 34)

The method of claim 34, wherein the modification causes reduced DNA damage response (DDR), reduced specificity in targeting in hematopoietic stem cells, reduced cytokine expression, or reduced inflammation.

### Claim 37 (depends on 32)

The method of claim 32, the cell is a eukaryotic cell.

### Claim 38 (depends on 37)

The method of claim 37, wherein the cell is a plant, animal, or human cell.

### Claim 39 (depends on 32)

The method of claim 32, comprising delivering the system via particles, vesicles, or one or more viral vectors.

### Claim 40 (depends on 39)

The method of claim 39, wherein the one or more viral vectors comprise an adenovirus-based vector, a lentivirus-based vector, or an adeno-associated virus-based vector.

### Claim 41 (depends on 32)

The method of claim 32, wherein the disease is cancer, a genetic disease or a neurodegenerative disease.

### Claim 42

A method for blocking a nucleotide sequence from cleavage, comprising: contacting a nucleic acid molecule comprising a target sequence that is subject to protection from cleavage by an endonuclease with (i) a dCas polypeptide and (ii) a guide nucleotide sequence encoding or comprising a crRNA sequence capable of hybridizing with a target sequence, wherein a complex of the dCas polypeptide and the guide nucleotide sequence binds to the target sequence, thereby blocking the target sequence from being cleaved by the endonuclease.
